39mon MSN
Nektar outlines $1B market opportunity for REZPEG in alopecia areata as Phase III plans advance
Q3 2025 Management View CEO Howard W. Robin welcomed Dr. Mary Tagliaferri back as Chief Medical Officer, noting her previous role in the successful Phase II program in atopic dermatitis and her return ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback